Suicidal Thoughts, Attempts Common Among Patients Starting Buprenorphine: Study

Philadelphia : There is a high prevalence of suicidal thoughts and attempts among patients with opioid use disorder (OUD) initiating buprenorphine, according to a study published online June 1 in Addiction Science & Clinical Practice.

Michelle R. Lent, Ph.D., from the Philadelphia College of Osteopathic Medicine, and colleagues examined the prevalence of factors associated with suicidality in adults with OUD initiating office-based buprenorphine treatment. The analysis included 244  completing a semistructured interview.

The researchers found that 37.70 percent of participants reported significant thoughts of suicide over their lifetime and 27.46 percent reported suicidal attempts over their lifetime. An increased risk for lifetime  was associated with a history of physical abuse (odds ratio [OR], 4.31) and having chronic pain-related conditions (OR, 3.28), a history of depression (OR, 3.30) or anxiety (OR, 7.47), and Latino/a/x ethnicity (OR, 2.66). An increased risk for lifetime suicide attempts was associated with a history of sexual abuse (OR, 2.89), Latino/a/x ethnicity (OR, 4.01), a history of depression (OR, 4.03) or anxiety (OR, 15.65), and having a chronic pain-related condition (OR, 2.43).

“Office-based  providing medication for OUD would benefit from integrated behavioral health services that can improve clinical response to the mental health needs of patients,” the authors write.

Journal Reference: Michelle R. Lent et al, Prevalence and predictors of suicidality among adults initiating office-based buprenorphine, Addiction Science & Clinical Practice (2023). DOI: 10.1186/s13722-023-00393-y

Related Posts

  • Pharma
  • February 10, 2025
  • 89 views
DGFT Amends Standard Input Output Norms For Erythromycin Stearate Tablets

Mumbai:  The Directorate General of Foreign Trade (DGFT), under the ministry of commerce & industry, has announced amendments to the Standard Input Output Norms (SION) for the export of erythromycin…

  • Pharma
  • February 10, 2025
  • 96 views
CSIR-NIIST Develops Technology To Convert Biomedical Waste Into Soil Additives

THIRUVANANTHAPURAM: CSIR-National Institute for Interdisciplinary Science and Technology (NIIST) in Thiruvananthapuram has developed a technology that converts pathogenic biomedical waste into value-added soil additives that eliminate the need for costly…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

An Index To Gauge States For Drug Enforcement, Improve Drug Quality

An Index To Gauge States For Drug Enforcement, Improve Drug Quality

DGFT Amends Standard Input Output Norms For Erythromycin Stearate Tablets

DGFT Amends Standard Input Output Norms For Erythromycin Stearate Tablets

CSIR-NIIST Develops Technology To Convert Biomedical Waste Into Soil Additives

CSIR-NIIST Develops Technology To Convert Biomedical Waste Into Soil Additives

As Always Ahead of Game in healthcare, Doc was first to vote too

As Always Ahead of Game in healthcare, Doc was first to vote too

Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister

Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister